GT Biopharma Reports First Quarter 2026 Financial Results
Stocks in this Quantisnow insightHealth Care
Historical context for GTBP
Across the 10 sessions after earlier GTBP headlines, the stock closed higher 8 times and lower 2 times, with a median move of 4.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GTBP | SPY |
|---|---|---|---|
| May 14, 2026 | GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | +40.3% | +0.8% |
| Mar 11, 2026 | GT Biopharma to Participate in the 38th Annual Roth Conference | +5.7% | -0.1% |
| Mar 2, 2026 | GT Biopharma Reports Full Year 2025 Financial Results | -2.3% | +0.1% |
| Feb 17, 2026 | GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference | -1.4% | +0.2% |
| Feb 3, 2026 | GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 | +2.3% | -0.8% |
| Jan 16, 2026 | THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle | +2.2% | -0.1% |
Quantisnow market dataNASDAQ
GTBP
GT Biopharma Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for GTBP
Full GTBP profile on Quantisnow Follow GTBP and get a push notification the moment its next story breaks.